Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole vs Standard-of-Care in Pediatric Pneumonia
NCT03439124Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Reversible Covalent Inhibitors
- Countries
- 4
01
Overview
A Phase 3 trial of ceftobiprole medocaril in hospital-acquired pneumonia (HAP), community acquired pneumonia (CAP), sponsored by Basilea Pharmaceutica. Started Nov 2017; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
hospital-acquired pneumonia (HAP)community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT03439124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439124.